

ABSTRACT

**PHARMACEUTICAL COMPOSITION FOR ORAL USE COMPRISING AN
ACTIVE PRINCIPLE LIABLE TO UNDERGO A LARGE FIRST
5 INTESTINAL PASSAGE EFFECT**

Use of an oral pharmaceutical composition to reduce the
intestinal passage effect on the active principle
contained in, the said composition being in the form of
10 a system which is self-microemulsifying on contact with
an aqueous phase, comprising:

- a therapeutically effective amount of the said
active principle;
- 15 - a lipophilic phase comprising a mixture of
glycerol mono-, di- and triesters and of PEG
mono- and diesters with at least one fatty acid
chosen from the group comprising C₈-C₁₈ fatty
acids;
- 20 - a surfactant phase comprising a mixture of
glycerol mono-, di- and triesters and of PEG
mono- and diesters with caprylic acid (C₈) and
capric acid (C₁₀);
- 25 - a co-surfactant phase comprising at least one
ester of a polyvalent alcohol with at least one
fatty acid chosen from the group comprising
caprylic esters of propylene glycol, lauric
esters of propylene glycol and oleic esters of
polyglycerol,
- the ratio TA/CoTA being between 0.2 and 6.

30